ストックスクリーナーアプリを入手
131.95
3.09%
3.95
Biogen Inc (BIIB) 最新ニュース
Biogen (NASDAQ:BIIB) Releases Earnings Results, Beats Expectations By $1.54 EPS - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Boosted by R Squared Ltd - MarketBeat
Jefferies Financial Group Inc. Has $6.84 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mackenzie Financial Corp Acquires 12,838 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Letko Brosseau & Associates Inc. Trims Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Seizert Capital Partners LLC Has $6.91 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Raised to $135.00 at Citigroup - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Raised to $219.00 at Royal Bank Of Canada - MarketBeat
Results: Biogen Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio (NASDAQ:BIIB) - Seeking Alpha
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Stock Analysis | Biogen OutlookA Cautious Technical Picture Amid Mixed Analyst Signals - AInvest
Biogen Reports Strong Q2 2025 Results, Raises Guidance - The Globe and Mail
Biogen Inc. Earnings Call Highlights Strong Growth and Raised Guidance - TipRanks
Biogen (BIIB) Rating Update: Citigroup Raises Price Target to $135 | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Updates FY 2025 Earnings Guidance - MarketBeat
RBC Capital Boosts Biogen (BIIB) Price Target After Strong Q2 Earnings - GuruFocus
Biogen’s New Study on Vumerity: Potential Market Impact - TipRanks
Biogen’s Phase 3 Trial on Felzartamab: A Potential Game-Changer for Kidney Transplant Recipients - TipRanks
RBC Capital Raises Price Target for Biogen (BIIB) to $219 | BIIB Stock News - GuruFocus
Biogen (BIIB) Price Target Adjusted Amid Growth Concerns - GuruFocus
Biogen beats earnings estimate and ups outlook - The Pharma Letter
Biogen to invest additional $2B in RTP hub - The North State Journal
Mild Cognitive Impairment Market Anticipated to Expand Rapidly - openPR.com
Biogen Inc. (NASDAQ:BIIB) Q2 2025 Earnings Call Transcript - Insider Monkey
Tredje AP fonden Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (BIIB) Receives Updated Analyst Rating from HC Wainwright & Co. | BIIB Stock News - GuruFocus
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Lowered by Y Intercept Hong Kong Ltd - MarketBeat
Biosimilars Market Expands with Patent Expiries and Growing - openPR.com
S&CO Inc. Buys New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc (BIIB) Q2 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Biogen Earnings: Modest Progress For Leqembi Launch; Full-Year Guidance Raised - Morningstar
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight - GuruFocus
Biogen’s Trading Volume Surges to $420M Ranking 341st as Rare Disease Sales and Institutional Buys Drive 1.07% Gains - AInvest
Biogen to Report Second Quarter 2025 Financial Results July 31, 2025 - Biogen
TD Asset Management Inc Sells 71,330 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen stock holds steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com Canada
AAIC 2025: Leqembi rides on real-world, subq autoinjector data - BioWorld MedTech
Biogen stock price target lowered to $144 at Morgan Stanley By Investing.com - Investing.com Canada
Biogen Edges Closer To Growth On Strong Q2 - insights.citeline.com
Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth - MSN
Biogen stock holds steady as Oppenheimer reiterates Outperform rating - Investing.com Australia
Biogen's Q2 2025 Earnings Call: Key Contradictions in LEQEMBI's Market Share, Pipeline Strategy, and Alzheimer’s Diagnostics - AInvest
Biogen plans to act on $8B to $10B in deal capacity - The Business Journals
Skandinaviska Enskilda Banken AB publ Has $6.39 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen signals Leqembi sales gaining momentum, lifts profit forecast - Reuters
Biogen’s Litifilimab Study: A Long-Term Hope for Lupus Treatment - TipRanks
Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Biogen Q2 2025 earnings beat forecasts, stock rises - Investing.com Australia
Why Is Biogen Stock Gaining Thursday?Biogen (NASDAQ:BIIB) - Benzinga
UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach - insights.citeline.com
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up - Yahoo Finance
Biogen Lifts Profit Guidance on Sales of Alzheimer’s Drug - Bloomberg.com
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Biogen raises annual profit forecast on strong demand for rare disease drugs - MarketScreener
Biogen Q2 2025 slides: Raised guidance, pipeline expansion drive stock higher - Investing.com India
Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook - MSN
Biogen Exceeds Q2 Revenue Expectations, Raises Full-Year Guidance - AInvest
Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen Q2 Results Top Estimates; Boosts FY25 Outlook - Nasdaq
Clark Estates Inc. NY Sells 4,504 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Reports Bullish Q2 - TradingView
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Biogen raises annual profit estimates on strong demand for rare disease drugs - 1470 & 100.3 WMBD
Biogen Inc (BIIB) Q2 2025 Earnings: Revenue Surges to $2.6 Billi - GuruFocus
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up - Yahoo Finance
Biogen stock rises on Q2 beat (BIIB:NASDAQ) - Seeking Alpha
Biogen (BIIB) Enhances 2025 Financial Outlook with Revised Guidance - GuruFocus
2.43%
大文字化:
|
ボリューム (24 時間):